Analysis Tools
neoplasm
|
• when bone marrow (BM) cells from polyinosinic-polycytidylic acid (pIpC)-treated mutant mice (CD45.2) are transplanted into lethally irradiated (CD45.1) recipient mice, less than 70% of recipients of mutant donor BM cells develop T cell acute lymphoblastic leukemia (T-ALL) with a slower progression and a median survival of 390 days post-transplantation versus 202 days for recipients of wild-type donor BM cells
• after oncogenic Nras activation by pIpC injection, mice develop a chronic myelomonocytic leukemia (CMML)-like disease with a significantly slower progression and a median survival of 173 days post-injection versus 152 days for control mice
|
